

We are advancing a diversified portfolio of product candidates derived from our four drug classes focused on the potential treatment of cancer, infectious diseases and other serious diseases of unmet patient need:

## Oncology

Drug class	Platform	Product candidate	Indication (target)	Phase 1	Phase 1/2	Phase 2	Phase 3	BioNTech rights <sup>1</sup>	Collaborator/ Partner
mRNA	FixVac	BNT111	Advanced, R/R melanoma					Fully owned <sup>2</sup>	
		BNT113	Metastatic/ R/R HPV16+ head and neck cancer						
		BNT116	1L metastatic NSCLC Advanced/metastatic NSCLC						
	iNeST	BNT122 (autogene cevumeran)	1L advanced melanoma					Collaboration	Genentech <sup>3</sup>
			Adjuvant colorectal cancer						
			Adjuvant pancreatic ductal adenocarcinoma						
			Multiple solid tumors						
	RiboMabs	BNT142	Multiple solid tumors (CD3xCLDN6)					Fully owned	
	RiboCytokines	BNT151	Multiple solid tumors (IL-2 variant)					Fully owned	
		BNT152 + BNT153	Multiple solid tumors (IL-7, IL-2)						
Cell therapies	CAR T cells + CARVac Neoantigen-based T cells	BNT211	Multiple solid tumors (CLDN6)					Fully owned	
		BNT221	Refractory metastatic melanoma					Fully owned	
Protein-based therapeutics	Next-generation immune checkpoint modulators	BNT311 / GEN1046 (acasinlimab)	aPD(L)1-R/R metastatic NSCLC (PD-L1x4-1BB) Multiple solid tumors (PD-L1x4-1BB)					Collaboration	Genmab
		BNT312 / GEN1042	Multiple solid tumors (CD40x4-1BB) <sup>4</sup>						
		BNT313 / GEN1053	Multiple solid tumors (CD27)						
		BNT314 / GEN1059	Multiple solid tumors (EpCAMx4-1BB)						
		BNT322 / GEN1056	Multiple solid tumors						
		BNT316 / ONC-392 (gotistobart)	aPD(L)1-R/R metastatic NSCLC (CTLA-4) Platinum-resistant ovarian cancer (CTLA-4) Metastatic castration-resistant prostate cancer (CTLA-4) Multiple solid tumors (CTLA-4)						
	Targeted cancer antibodies	BNT321	Pancreatic cancer (sLea)					Fully owned	
		Antibody-drug conjugates	BNT323 / DB-1303	Multiple solid tumors (HER2) 2L+, HR+/HER2-low metastatic breast cancer (HER2)					Collaboration
	BNT324 / DB-1311		Multiple solid tumors (B7H3)						
	BNT325 / DB-1305		Multiple solid tumors (TROP2)						
BNT326 / YL202	Multiple solid tumors (HER3)								
SMI <sup>5</sup>	Toll-like receptor binding	BNT411	Multiple solid tumors (TLR7)					Fully owned	

We are advancing a diversified portfolio of product candidates derived from our four drug classes focused on the potential treatment of cancer, infectious diseases and other serious diseases of unmet patient need:

## Infectious Diseases

Drug class	Product candidate	Indication	Phase 1	Phase 1/2	Phase 2	Phase 3	Commercial	BioNTech rights	Collaborator/ Partner		
mRNA	BNT162b2		[Progress bar spanning all phases]								
	BNT162b2+BNT162b4 (T-cell enhancing)	COVID-19	[Progress bar in Phase 1]						Collaboration	Pfizer Fosun Pharma	
	BNT162b5/6/7 (Stabilized spike antigen)		[Progress bar spanning Phase 1 to Phase 2]								
	BNT162b2+BNT161 <sup>6</sup>	COVID-19 – Influenza combination	[Progress bar spanning Phase 1 to Phase 3]							Collaboration	Pfizer
	BNT161	Influenza	[Progress bar spanning Phase 1 to Phase 3]							Collaboration <sup>7</sup>	Pfizer
	BNT163	HSV	[Progress bar in Phase 1]						Collaboration	University of Pennsylvania	
	BNT164	Tuberculosis <sup>8</sup>	[Progress bar in Phase 1]						Fully owned	Funded by Bill & Melinda Gates Foundation	
	BNT165	Malaria <sup>9</sup>	[Progress bar spanning Phase 1 to Phase 1/2]							Fully owned	
	BNT166	Mpox	[Progress bar spanning Phase 1 to Phase 1/2]							Fully owned	Funded by CEPI <sup>10</sup>
	BNT167	Shingles	[Progress bar spanning Phase 1 to Phase 1/2]							Collaboration	Pfizer

1 For further details about BioNTech's rights see quarterly reports under <https://investors.biontech.de/financials-filings/quarterly-reports>.

2 FixVac platform is fully owned by BioNTech. The BNT111 and BNT116 Phase 2 trials are jointly conducted with Regeneron as part of a cost-sharing strategic collaboration.

3 A member of the Roche group

4 Two Phase 1/2 clinical trials in patients with solid tumors are ongoing in combination with IC±/- chemotherapy.

5 Small molecule immunomodulators

6 The COVID-19-Influenza combination is a Phase 3 trial in partnership with Pfizer. Further development is subject to entering into a definitive agreement.

7 Out-licensed to Pfizer

8 Two Phase 1 clinical trials are ongoing (NCT05537038, Germany and NCT05547464, Republic of South Africa).

9 A Phase 1 clinical trial (NCT05581641) and a Phase 1/2 clinical trial (NCT06069544) are ongoing.

10 Coalition for Epidemic Preparedness Innovations (CEPI)